Revive Therapeutics (RVV) News Today C$0.08 +0.01 (+14.29%) As of 07/22/2019 Add Compare Share Share Headlines Stock AnalysisBuy This Stock RVV Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 13, 2025 | finanznachrichten.deRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 12, 2025 | financialpost.comRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureMay 12, 2025 | financialpost.comRevive Therapeutics Ltd. (RVV.NE)April 18, 2025 | ca.finance.yahoo.comRevive Therapeutics Ltd.: Revive Therapeutics to Investigate Bucillamine's Potential in Cancer TreatmentApril 10, 2025 | finanznachrichten.deRevive Therapeutics to Investigate Bucillamine’s Potential in Cancer TreatmentApril 10, 2025 | financialpost.comRevive Therapeutics Announces Acquisition of Molecular Hydrogen ProgramApril 1, 2025 | markets.businessinsider.comDiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral SclerosisMarch 3, 2025 | markets.businessinsider.comRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureJanuary 8, 2025 | financialpost.comRevive Therapeutics Ltd. (RVVTF)November 24, 2024 | finance.yahoo.comRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent ExposureNovember 3, 2024 | uk.finance.yahoo.comRevive Therapeutics provides update on research study of bucillamineNovember 1, 2024 | markets.businessinsider.comRevive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical CountermeasuresSeptember 18, 2024 | markets.businessinsider.comRevive Therapeutics Ltd. (RVV.CN)September 3, 2024 | ca.finance.yahoo.comRevive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral InfectionsAugust 29, 2024 | tmcnet.comRevive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVIDApril 23, 2024 | tmcnet.comRevive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic ProductApril 18, 2024 | markets.businessinsider.comRevive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDMarch 27, 2024 | finanznachrichten.deRevive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVIDMarch 27, 2024 | finance.yahoo.comRevive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDMarch 19, 2024 | finanznachrichten.deRevive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVIDMarch 19, 2024 | markets.businessinsider.comRevive Therapeutics Ltd.: Revive Therapeutics Provides Corporate UpdateMarch 12, 2024 | finanznachrichten.deRevive Therapeutics Provides Corporate UpdateMarch 12, 2024 | financialpost.comRevive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,110February 26, 2024 | markets.businessinsider.comRevive Therapeutics Explores the Use of Bucillamine for Long COVIDFebruary 1, 2024 | markets.businessinsider.comRevive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,500January 31, 2024 | markets.businessinsider.comRevive Therapeutics Ltd. Announces Offering of Up to $3 MillionJanuary 24, 2024 | financialpost.comRevive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development CanadaJanuary 16, 2024 | tmcnet.comRevive Therapeutics Ltd.: Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of BucillamineJanuary 10, 2024 | finanznachrichten.deRevive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of BucillamineJanuary 10, 2024 | markets.businessinsider.comTravere Therapeutics expects Q4 net product sales from continuing operations to be about $40MJanuary 8, 2024 | msn.comRevive Therapeutics Announces Results of Annual General and Special Meeting of ShareholdersDecember 20, 2023 | markets.businessinsider.comRevive Therapeutics To Work With Attwill For Development Of Lyophilized Formulation Of BucillamineDecember 18, 2023 | markets.businessinsider.comRevive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of BucillamineDecember 18, 2023 | financialpost.comRevive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent ExposureOctober 17, 2023 | markets.businessinsider.comRevive Therapeutics Agrees With DRDC To Evaluate Bucillamine For Nerve Agent ExposureOctober 17, 2023 | markets.businessinsider.comRevive Therapeutics Ltd.: Revive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentOctober 11, 2023 | finanznachrichten.deRevive Therapeutics Provides Update of Novel Bucillamine Formulation DevelopmentOctober 11, 2023 | tmcnet.comItaly turns to Kyrgyz shepherds to revive Sardinian farmingSeptember 28, 2023 | ft.comRevive Therapeutics Ltd.: Revive Therapeutics Announces Initiation of Novel Bucillamine Formulation DevelopmentAugust 22, 2023 | finanznachrichten.deRevive Therapeutics Announces Initiation of Novel Bucillamine Formulation DevelopmentAugust 22, 2023 | stockhouse.comNJ volunteer firefighter helps revive man who collapsed during basketball gameAugust 21, 2023 | cbsnews.comRevive Therapeutics Announces Filing of Patent for Bucillamine in the Treatment of Exposure to Chemical Warfare AgentsJuly 28, 2023 | stockhouse.comRVV.CN - Revive Therapeutics Ltd.July 11, 2023 | finance.yahoo.comRevive Therapeutics Announces Results of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19July 6, 2023 | stockhouse.comHow to Revive an Old Computer for Your Kid—or Decide on a New OneJuly 3, 2023 | nytimes.comRevive Therapeutics staying the course on Phase 3 trial of Bucillamine in Covid-19 patients after meeting with FDAMay 30, 2023 | proactiveinvestors.comRevive Therapeutics halts Bucillamine for COVID-19 study; seeks data evaluation to inform next stepsMay 12, 2023 | proactiveinvestors.comRevive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19May 2, 2023 | benzinga.comRevive Therapeutics says date set for independent Data and Safety Monitoring Board meeting for its Bucillamine Phase 3 clinical trialMay 2, 2023 | proactiveinvestors.com Get Revive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVV and its competitors with MarketBeat's FREE daily newsletter. Email Address RVV Media Mentions By Week RVV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVV News Sentiment▼0.000.87▲Average Medical News Sentiment RVV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVV Articles This Week▼00▲RVV Articles Average Week Get Revive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HEM News SBM News KNE News IOT News FRX News TH News APS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CVE:RVV) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revive Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Revive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RVV Stock Free RVV Stock Alerts